Drug profile · INN
vedolizumab
ENTYVIO
vedolizumab (ENTYVIO) is a integrin alpha-4/beta-7 inhibitor. Associated with Lacuna Pharma Pty Ltd. Route of administration: injection. Current US regulatory status: approved.
Drug details — vedolizumab
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 1
- Programs
- 40
- Data quality
- 0.89
Quick answer
vedolizumab (ENTYVIO) is a integrin alpha-4/beta-7 inhibitor. Associated with Lacuna Pharma Pty Ltd. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Integrin alpha-4/beta-7 inhibitor
Primary target: Integrin alpha-4/beta-7
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
| NMPA | clinical trials | — |
Pipeline programs
Related patents
Frequently asked questions
What is vedolizumab?
vedolizumab (ENTYVIO) is a integrin alpha-4/beta-7 inhibitor. Associated with Lacuna Pharma Pty Ltd. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for vedolizumab?
ENTYVIO is a marketed brand name for vedolizumab. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of vedolizumab?
vedolizumab has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.